Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2002 | 2 |
2003 | 1 |
2005 | 1 |
2007 | 1 |
2010 | 1 |
2011 | 1 |
2019 | 1 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Kidney Int. 2019 Jul;96(1):231-244. doi: 10.1016/j.kint.2019.01.041. Epub 2019 Feb 27.
Kidney Int. 2019.
PMID: 31027892
Free article.
Clinical Trial.
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.
Smith IE, Pierga JY, Biganzoli L, Cortés-Funes H, Thomssen C, Pivot X, Fabi A, Xu B, Stroyakovskiy D, Franke FA, Kaufman B, Mainwaring P, Pienkowski T, De Valk B, Kwong A, González-Trujillo JL, Koza I, Petrakova K, Pereira D, Pritchard KI; ATHENA Study Group.
Smith IE, et al.
Ann Oncol. 2011 Mar;22(3):595-602. doi: 10.1093/annonc/mdq430. Epub 2010 Sep 5.
Ann Oncol. 2011.
PMID: 20819780
Free article.
Clinical Trial.
Item in Clipboard
Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort.
Dieleman JP, Sturkenboom MC, Jambroes M, Gyssens IC, Weverling GJ, ten Veen JH, Schrey G, Reiss P, Stricker BH; Athena Study Group.
Dieleman JP, et al.
Arch Intern Med. 2002 Jul 8;162(13):1493-501. doi: 10.1001/archinte.162.13.1493.
Arch Intern Med. 2002.
PMID: 12090886
Clinical Trial.
Item in Clipboard
Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study.
Wit FW, Blanckenberg DH, Brinkman K, Prins JM, van der Ende ME, Schneider MM, Mulder JW, de Wolf F, Lange JM; ATHENA Study Group.
Wit FW, et al.
AIDS. 2005 Feb 18;19(3):345-8.
AIDS. 2005.
PMID: 15718848
Item in Clipboard
Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort.
Dieleman JP, Jambroes M, Gyssens IC, Sturkenboom MC, Stricker BH, Mulder WM, de Wolf F, Weverling GJ, Lange JM, Reiss P, Brinkman K; ATHENA Study Group.
Dieleman JP, et al.
AIDS. 2002 Mar 29;16(5):737-45. doi: 10.1097/00002030-200203290-00009.
AIDS. 2002.
PMID: 11964530
Item in Clipboard
Quality of life after starting highly active antiretroviral therapy for chronic HIV-1 infection at different CD4 cell counts.
Nieuwkerk PT, Hillebrand-Haverkort ME, Vriesendorp R, Frissen PH, de Wolf F, Sprangers MA; ATHENA Study Group.
Nieuwkerk PT, et al.
J Acquir Immune Defic Syndr. 2007 Aug 15;45(5):600-1. doi: 10.1097/QAI.0b013e318074efbf.
J Acquir Immune Defic Syndr. 2007.
PMID: 17704686
No abstract available.
Item in Clipboard
Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations.
Burger DM, Hugen PW, Aarnoutse RE, Hoetelmans RM, Jambroes M, Nieuwkerk PT, Schreij G, Schneider MM, van der Ende ME, Lange JM; ATHENA Study Group.
Burger DM, et al.
Ther Drug Monit. 2003 Feb;25(1):73-80. doi: 10.1097/00007691-200302000-00011.
Ther Drug Monit. 2003.
PMID: 12548148
Item in Clipboard
Cite
Cite